A study conducted on a large population-based cohort (FINIRISK 1997 cohort) initially established that Gal-3 counts as a predictor of three major endpoints—namely, all-cause mortality, cardiovascular death and incident heart failure—after adjusting for the parameters of the Framingham risk score. Here, LGALS3 is linked to heart failure.